Webb telescope spots strong 'hints'of life on distant planet

PARIS (AFP) — Astronomers announced Thursday that they had detected the most promising "hints" of potential life on a planet beyond our solar system, though other scientists expressed skepticism.
There has been vigorous debate in scientific circles about whether the planet K2-18b, which is 124 light years away in the Leo constellation, could be an ocean world capable of hosting microbial life.
Using the James Webb Space Telescope, a British-US team of researchers detected signs of two chemicals in the planet's atmosphere long considered to be "biosignatures" indicating extraterrestrial life.
On Earth, the chemicals dimethyl sulfide (DMS) and dimethyl disulfide are produced only by life, mostly microscopic marine algae called phytoplankton.
The researchers emphasized caution, saying that more observations were needed to confirm these findings, and that they were not announcing a definitive discovery.
But the implications could be huge, according to Nikku Madhusudhan, a Cambridge University astrophysicist and lead author of the study, published in The Astrophysical Journal Letters.
"What we are finding at this point are hints of possible biological activity outside the solar system," he told a press conference.
"Frankly, I think this is the closest we have come to seeing a feature that we can attribute to life."
But outside experts pointed to disputes over previous discoveries about the exoplanet, adding that these chemicals could have been created by unknown means having nothing to do with life.
More than eight times the mass of Earth and 2.5 times as big, K2-18b is a rare exoplanet that orbits its star in a habitable or "goldilocks" zone.
This means it is neither too hot nor too cold to have liquid water, considered the most important ingredient for life.
Telescopes observe such far-off exoplanets when they cross in front of their star, allowing astronomers to analyze how molecules block the light streaming through their atmosphere.
In 2023, the Webb telescope detected methane and carbon dioxide in K2-18b's atmosphere, the first time such carbon-based molecules were detected on an exoplanet in a habitable zone.
It also detected weak signals of the chemical DMS, leading astronomers to turn Webb towards the planet again a year ago, this time using its mid-infrared instrument to detect different wavelengths of light.
They found much stronger signs of the chemicals, though still well below the "five sigma" threshold of statistical significance scientists seek for such discoveries.
Even if the results are confirmed, it would not necessarily mean that the planet is home to life.
Last year, scientists found traces of DMS on a comet, which suggested it can be produced in non-organic ways.
However the concentration of the chemical observed on K2-18b appears to be thousands of times stronger than levels on Earth, strongly suggesting a biological origin, Madhusudhan said.
Are we alone?
K2-18b has long been considered the premier candidate for a "hycean planet" — an ocean world bigger than Earth with a hydrogen-rich atmosphere.
These planets would not be expected to be home to intelligent alien life, but rather tiny microbes similar to those in Earth's oceans billions of years ago.
Some research has questioned whether the currently proposed hycean planets are too close to their stars to support liquid water, including K2-18b, which orbits its star every 33 days.
Raymond Pierrehumbert, a planetary physics professor at Oxford University, has conducted separate research indicating K2-18b is too hot for life.
If the planet did have water, it would be "hellishly hot" and uninhabitable, he told Agence France-Presse, adding that oceans of lava were more plausible.
Sara Seager, a professor of planetary science at MIT, called for patience, pointing to previous claims of water vapor in K2-18b's atmosphere that turned out to be a different gas.
And within our solar system, Mars, Venus and moons such as Saturn's Enceladus all have "more chance to be realised as life-hosting," she told Agence France-Presse.
Madhusudhan estimated that it would take just 16 to 24 more hours of Webb's time to confirm their findings, which could happen in the next few years.
Even beyond K2-18b, Madhusudhan said Webb and future telescopes could allow humanity to discover life outside our home planet sooner than one might think.
"This could be the tipping point, where suddenly the fundamental question of whether we're alone in the universe is one we're capable of answering," he said.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Korea Herald

a day ago

• Korea Herald

[Bio USA] SK Biopharmaceuticals CEO highlights resilience, open innovation amid global shifts

Korea Herald correspondent BOSTON — SK Biopharmaceuticals CEO Lee Dong-hoon underscored the company's preparedness for potential US tariff changes and emphasized the critical role of open innovation in shaping the future of global pharmaceuticals. 'We've weathered volatility in our share price over the past year, but the impact of potential price cuts has been minimal,' Lee said Thursday during a press conference on the sidelines of the 2025 Bio USA. 'Our direct-to-market sales model remains fundamentally solid.' He recalled a particularly tense moment earlier this year when shifting US tariff policies posed logistical challenges. In April, the company rushed to transport finished products from Canada into the US before a new tariff deadline. 'When the final truck finally cleared customs, everyone burst into applause,' he recounted. To prevent such risks from recurring, the company now assembles finished products in Canada and ensures shipments cross the border ahead of any policy changes. Looking ahead, SK Biopharmaceuticals is evaluating Puerto Rico as a potential US-based manufacturing site, leveraging its status as a US territory and pharmaceutical hub. 'Canada is cost-effective for now, but we're preparing for every scenario,' Lee said, noting the company's tariff risk is now 'close to zero' for the year. Lee also expressed confidence in the company's long-term growth. 'We've already announced our goal to hit 1 trillion won ($728 million) in sales by 2029, and we're on track,' he said, citing consistent profitability since last year. A cornerstone of SK Biopharmaceuticals' strategy is open innovation. Instead of relying solely on internal research and development, the company is partnering with universities, biotech firms and research institutions. 'Major global pharmaceutical firms are moving away from in-house basic research, and so are we. When you can collaborate and generate results at a fraction of the cost, your possibilities expand," he explained. The CEO emphasized the importance of tapping into underutilized technologies at US universities and biotech startups to diversify the company's pipeline, moving beyond its core focus on epilepsy into areas like oncology. Artificial intelligence is another major focus area. Lee highlighted the company's work on EEG-based seizure prediction models in collaboration with European and South American partners, along with AI algorithm development trials currently underway in Korea. 'AI is no longer optional. It's essential in every part of the business,' he said. One standout partnership is with PhnyX Lab, whose AI-driven automation of clinical documentation significantly reduced paperwork. 'Even our US team, which was initially skeptical, was blown away,' Lee said, calling the shift 'Copernican' in scale for how it will reduce time and cost. The CEO also outlined plans to build a global digital platform for epilepsy patients — a space where patients and physicians can share experiences and insights. 'It's not about selling drugs,' he clarified. 'It's about collecting data to inform AI-powered marketing, drug development and clinical trial design.' The company is looking three to five years ahead, aiming to build an ecosystem where shared data drives innovation across functions. In the US, SK Biopharmaceuticals is intensifying its engagement with health care providers. Lee has personally met with dozens of physicians this year, aiming for 100 meetings, to gather insights that will shape lifecycle strategies such as patent extensions, expanded indications and new formulations like IV delivery. Meanwhile, SK Biopharmaceuticals has invested in targeted TV and YouTube campaigns for its flagship epilepsy drug, Xcopri (cenobamate). Its 'Road to Reduction' campaign drew 9.37 million views in just one month, signaling the brand's growing visibility and leadership in the epilepsy treatment market.

Korea Herald

4 days ago

• Korea Herald

Warning signs on climate flashing: scientists

PARIS (AFP) — From carbon pollution to sea-level rise to global heating, the pace and level of key climate change indicators are all in uncharted territory, more than 60 top scientists warned Thursday. Greenhouse gas emissions from burning fossil fuels and deforestation hit a new high in 2024 and averaged, over the last decade, a record 53.6 billion tons per year — that is 100,000 tons per minute — of CO2 or its equivalent in other gases, they reported in a peer-reviewed update. Earth's surface temperature last year breached 1.5 degrees Celsius for the first time, and the additional CO2 humanity can emit with a two-thirds chance of staying under that threshold long-term — our 1.5 C "carbon budget" — will be exhausted in a couple of years, they calculated. Investment in clean energy outpaced investment in oil, gas and coal last year two-to-one, but fossil fuels account for more than 80 percent of global energy consumption, and growth in renewables still lags behind new demand. Included in the 2015 Paris climate treaty as an aspirational goal, the 1.5 C limit has since been validated by science as necessary for avoiding a catastrophically climate-addled world. The hard cap on warming to which nearly 200 nations agreed was "well below" two degrees, commonly interpreted to mean 1.7 C to 1.8 C. "We are already in crunch time for these higher levels of warming," co-author Joeri Rogelj, a professor of climate science and policy at Imperial College London, told journalists in a briefing. "The next three or four decades is pretty much the timeline over which we expect a peak in warming to happen." No less alarming than record heat and carbon emissions is the gathering pace at which these and other climate indicators are shifting, according to the study, published in Earth System Science Data. Human-induced warming increased over the last decade at a rate "unprecedented in the instrumental record," and well above the 2010-2019 average registered in the UN's most recent Intergovernmental Panel on Climate Change report, in 2021. The new findings — led by the same scientists using essentially the same methods — are intended as an authoritative albeit unofficial update of the benchmark IPCC reports underpinning global climate diplomacy. They should be taken as a reality check by policymakers, the authors suggested. "I tend to be an optimistic person," said lead author Piers Forster, head of the University of Leed's Priestley Centre for Climate Futures. "But if you look at this year's update, things are all moving in the wrong direction." The rate at which sea levels have shot up in recent years is also alarming, the scientists said. After creeping up, on average, well under two millimetres per year from 1901 to 2018, global oceans have risen 4.3 millimiters annually since 2019. An increase in the ocean watermark of 23 centimeters — just over the width of an A4 sheet of paper — over the last 125 years has been enough to imperil many small island states and hugely amplify the destructive power of storm surges worldwide. An additional 20 centimeters of sea level rise by 2050 would cause $1 trillion in flood damage annually in the world's 136 largest coastal cities, earlier research has shown. Another indicator underlying all the changes in the climate system is Earth's so-called energy imbalance, the difference between the amount of solar energy entering the atmosphere and the smaller amount leaving it. So far, 91 percent of human-caused warming has been absorbed by oceans, sparing life on land. But the planet's energy imbalance has nearly doubled in the last 20 years, and scientists do not know how long oceans will continue to massively soak up this excess heat. Dire future climate impacts worse than what the world has already experienced are already baked in over the next decade or two. But beyond that, the future is in our hands, the scientists made clear. "We will rapidly reach a level of global warming of 1.5 C, but what happens next depends on the choices which will be made," said co-author and former IPCC co-chair Valerie Masson-Delmotte. The Paris Agreement's 1.5 C target allows for the possibility of ratcheting down global temperatures below that threshold before century's end. Ahead of a critical year-end climate summit in Brazil, international cooperation has been weakened by the US withdrawal from the Paris Agreement. President Donald Trump's dismantling of domestic climate policies means the United States is likely to fall short on its emissions reduction targets, and could sap the resolve of other countries to deepen their own pledges, experts say.

Korea Herald

10-06-2025

• Korea Herald

ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore

SINGAPORE, June 10, 2025 /PRNewswire/ -- ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to create and grow MedTech ventures in Singapore. This partnership will support venture creation, product development, and commercialisation by bringing together ClavystBio and two national initiatives hosted by A*STAR — MedTech Catapult and the Diagnostics Development Hub (DxD Hub) — along with A*STAR's broader MedTech and venture creation capabilities. The partnership comes amid growing momentum in Singapore's biomedical landscape, with MedTech output reaching S$20 billion in 2023. [1] As Asia's MedTech market is projected to grow to US$225 billion (S$304 billion) by 2030, [2] these efforts aim to better position Singapore-based innovations to scale and enter new markets. Over this two-year partnership, the parties will work towards the co-creation of new MedTech ventures, investments into A*STAR affiliated companies, and fostering collaborations between A*STAR and ClavystBio's portfolio companies. By combining complementary strengths — from research and engineering to venture building and funding — the partnership aims to identify promising technologies, shape MedTech projects for market readiness, and support new venture formation to strengthen Singapore's innovation-driven MedTech ecosystem. The partnership will focus on several key areas: "This partnership highlights ClavystBio's commitment to nurturing globally successful medical devices, digital health, and diagnostics companies from Singapore," said Mr Anselm Tan, Digital Health & MedTech Lead at ClavystBio. "By combining ClavystBio's investment and venture-building expertise with A*STAR's deep scientific capabilities and productisation platforms, we are cultivating an ecosystem primed for innovation and commercial success. "A*STAR is committed to nurturing a dynamic MedTech ecosystem that bridges innovation with deep tech companies," said Ms Irene Cheong, Assistant Chief Executive (Innovation & Enterprise) at A*STAR. "This MoU builds on an existing collaboration with ClavystBio and marks a significant step forward in our joint efforts to co-create and grow globally investible MedTech ventures. Through national productisation platforms like MedTech Catapult and DxD Hub, combined with A*STAR's venture creation capabilities, we aim to commercialise more innovations from lab to market and grow a vibrant MedTech ecosystem in Singapore." About ClavystBio ClavystBio is a life sciences investor and venture builder set up by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with founders and entrepreneurs to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing start-ups together, we foster a vibrant and supportive community. About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit About Diagnostics Development Hub (DxD Hub) The Diagnostics Development Hub is a national platform hosted by the Agency for Science, Technology and Research (A*STAR). DxD Hub aims to accelerate the transformation of innovations into clinically validated diagnostic devices that are ready for market adoption. Through impactful products, empowering local enterprises and anchoring global companies in Singapore, DxD Hub contributes to the development of an effective diagnostic devices' ecosystem in Singapore. For ongoing news, visit About MedTech Catapult MedTech Catapult (MC) is a national initiative designed to accelerate the product development and commercialisation of high-value life science instruments and regulated medical devices. MC partners with product owners, local contract manufacturers (CMs), and leverages external design houses, and other key stakeholders to guide innovations from concept to market. Their goal is to strengthen Singapore's medtech ecosystem by providing dedicated engineering, quality assurance, regulatory affairs, clinical affairs, project management and commercialisation support to derisk and support products towards commercialisation and market adoption whilst supporting pull-through to local manufacturing.